In the mucinous subtype of ovarian carcinoma, downregulation of PLK1 with siRNA as well as pharmacological PKL1 inhibition (Volasertib® and Onvansertib®, both highly selective ATP-competitive PLK1 inhibitors) [276] in a xenograft model interferes with cell proliferation inducing mitotic arrest at G2/M phase leading to endoduplication as well as apoptosis [277]. Here, PLK1 is linked to ovarian carcinoma.